SC
CSTL icon

Stephens Consulting’s Castle Biosciences CSTL Stock Holding History

Stephens Consulting’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$41 – 575
2025
Q2 		$41 Buy
+2
New +$37 ﹤0.01% 1130

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's CSTL Position: Q3 2025 in Review

Stephens Consulting sold out of Castle Biosciences (CSTL) in Q3 2025, closing a stake of 2 shares — an estimated $41 sold.

Stephens Consulting first reported a position in CSTL in Q2 2025 and held it in 1 quarter. The position peaked at $41 in Q2 2025. 173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Stephens Consulting reported no remaining Castle Biosciences position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 2 Castle Biosciences shares in Q3 2025, an estimated $41.
  • Stephens Consulting first reported a position in Castle Biosciences in Q2 2025 and held it in 1 quarter.
  • Stephens Consulting's Castle Biosciences position peaked at $41 in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.